CLNN
- Clene Inc.
()
Overview
Company Summary
Clene Inc. (CLNN) is a biopharmaceutical company that specializes in developing and commercializing novel nanotechnology-based therapeutics for the treatment of neurodegenerative diseases. With a focus on diseases such as Alzheimer's and Parkinson's, Clene aims to revolutionize the way these conditions are addressed.
The company's primary technology platform is called Nanocatalysis, which involves the use of proprietary metallic nanoparticles to enhance the body's natural processes of cellular energetics and homeostasis. By applying this technology, Clene seeks to improve the energy metabolism and repair mechanisms within cells, ultimately leading to improved neuronal function and better outcomes for patients.
Clene's flagship product candidate is CNM-Au8, an orally administered nanocatalytic gold compound. This innovative therapy has shown promising potential to treat neural disorders by supporting the normal energetics and function of nerve cells, reducing oxidative stress, and promoting neuroprotection. CNM-Au8 is currently being evaluated in clinical trials for various indications, including neurodegenerative diseases and rehabilitation after acute injuries to the central nervous system.
In addition to CNM-Au8, Clene has an extensive pipeline of other nanocatalytic therapeutic candidates targeting a range of neurodegenerative diseases. By leveraging their expertise in nanotechnology and cellular energetics, the company is committed to advancing scientific understanding and delivering innovative solutions to address the significant unmet needs in the field of neurology.
Overall, Clene Inc. is dedicated to developing groundbreaking therapies based on nanocatalysis to improve the lives of patients suffering from neurodegenerative diseases, ultimately aiming to redefine the treatment landscape in this critical area of healthcare.